SHIELD study: a multicenter, open-label, single-arm trial to evaluate the safety, pharmacokinetics and antiviral activity of fostemsavir in combination with optimized background therapy (OBT) in children and adolescents with HIV who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class antiretroviral (ARV) resistance

Abstract Background Multi-drug resistant HIV-1 is a growing global concern in children, highlighting the need for new antiretroviral drugs. Fostemsavir, recently approved for adults with multi-drug resistant HIV-1 and limited treatment options, has not yet been evaluated in the pediatric population....

詳細記述

書誌詳細

主要な著者:	Carlos Grasa, Nicolas Salvadori, Alessandra Nardone, Kanchana Than-in-at, Alicia Koblansky, Chris Parry, Nilay Thakkar, Marcia Wang, Carlo Giaquinto, Pablo Rojo, Tim R. Cressey
フォーマット:	Artigo
言語:	Inglês
出版事項:	BMC 2026-02-01
シリーズ:	BMC Infectious Diseases
主題:	Fostemsavir Antiretrovirals HIV Multi-drug resistance Children Adolescents
オンライン･アクセス:	https://doi.org/10.1186/s12879-026-12806-9
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!